Nobel Prize for novel cancer therapies
4 October 2018
Two of the men responsible for the discovery and development of checkpoint inhibitors, therapies that revolutionised the way metastatic melanoma patients are treated, extending lives and improving quality of life for countless patients, were awarded this year’s Nobel Prize in Physiology or Medicine.
Professor James P. Allison from MD Anderson Cancer Centre, and Professor Tasuku Honjo from Kyoto University were jointly awarded the Nobel Prize for their separate work from the early 1990’s, where they each discovered a different protein that plays a major role in regulating the immune system.
The immune system is a balancing act – it is constantly trying to fight off foreign invaders, like viruses and bacteria, without harming the body – that relies heavily on an intricate system of brakes and accelerators. Sometimes the balance is off, resulting in autoimmune diseases where the immune system attacks the body, or diseases like cancer, where the immune system does not recognise that there is anything amiss.
Both Professor Allison and Professor Honjo discovered molecules that act as a brake in the immune system, halting its action and allowing cancers to grow. In Professor Allison’s research, he showed that blocking the molecule he discovered, CTLA-4, could switch off the brake, allowing the immune system to recognise a tumour and attack it. His work lead to the development of the melanoma fighting drug ipilimumab. Professor Honjo discovered the protein PD-1, and found that blocking it allows the immune system to recognise cancer as an invader and mount an immune response. This led to the manufacture of the immunotherapies nivolumab and pembrolizumab.
Ipilimumab, nivolumab and pembrolizumab are now used extensively to treat metastatic melanoma, working to help patient’s own bodies to recognise and fight the disease. Since these treatments have become available, melanoma patients have a better prognosis than ever before.
The two men will receive their Nobel Prizes at a formal ceremony in Stockholm in December. Five different Nobel Prizes are awarded every year, with the Nobel Prize in Physiology or Medicine given to up to three people who have made outstanding discoveries in the fields of medicine or the life sciences. Previous Nobel laureates include three of the men responsible for the discovery of DNA, and the three men who discovered penicillin.
Photograph: Niklas Elmehed/Twitter:NobelPrize
Two of the world’s best minds in melanoma have taken over the academic and clinical leadership of Melanoma Institute Australia (MIA). Professor Georgina Long and Professor Richard Scolyer are the new Conjoint Medical Directors of MIA, and are shaping the future direction of melanoma research, treatment and education.
Meet Georgia, our Clinica Nurse Consultant who provides vital care and education for patients throughout their treatment.
Australia, we need to talk. This week’s dramatic episodes of Married At First Sight have highlighted a tragedy which is ripping Australian families apart. Yet no one is talking about it.
To celebrate International Women's Day 2017, MIA shares how some of the women who inspire the way we work every day, are showing their commitment to accelerate gender parity.
We welcome Mr Grant King to the position of Chairman of the Board of Melanoma Institute Australia, following the retirement of Mr Reg Richardson AM who led the organisation for 10 years.
Congratulations to PhD Student, Tuba Nur Gide who was awarded a NSW National Council of Women Australia Day Award for her PhD research work.
Melanoma Institute Australia, is joining forces with the Wollongong Wolves Football Club in the battle to reduce Australia’s melanoma rates.
A new research project will evaluate the benefits and economic implications of CT and PET/CT imaging in patients with asymptomatic Stage III melanoma.
Sunscreen tips for a skin smart summer with the help of Professor Pascale Guitera, Dermatologist Associate for Melanoma Institute Australia.
Although survival rates for people with skin melanoma are increasing, these promises of hope are not being seen in uveal melanoma. Researchers are desperately trying to uncover new ways to treat this disease.
Lucinda Ryan and Carole Renouf talking about melanoma preventation and awareness on 720 ABC Perth.
Research projects led by MIA have been awarded almost $6 million in the latest NHMRC funding round which will enable vital progression of research into melanoma prevention and treatment.
The last decade has seen a surge in therapeutic options for advanced melanoma patients, thanks to research. However, not every patient responds to treatment and researchers are taking on the challenge to find out why.
Our first Global Melanoma Research Report shares selected research from around the world and here at MIA that is making a difference to the lives of melanoma patients now and in the future.
After 18 years as Director of the Sydney Melanoma Unit and then Executive Director of Melanoma Institute Australia, Professor John Thompson AO will step down from the position at the end of 2016.
Australian melanoma clinical practice guidelines have been published on a wiki platform for the first time as researchers try to keep up to date with emerging evidence.
Carole Renouf, CEO of Melanoma Institute Australia is asking young Australians who have been affected by melanoma to share their experiences with her.
Melanoma Institute Australia CEO Carole Renouf wants to make sure Aussies remember to take care of our skin as the festive season draws closer and we spend more time in the sun.
Can an individual’s risk factors for melanoma be used to tailor skin self-examinations and surveillance programs?
Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).